Nanoparticles in induced sputum – a window to airway inflammation among active smokers

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Reitsma MB, Kendrick PJ, Ababneh E et al. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet 397(10292), 2337–2360 (2021).
  MedlineGoogle Scholar
• 2. Jha P, Ranson MK, Nguyen SN, Yach D. Estimates of global and regional smoking prevalence in 1995, by age and sex. Am. J. Public Health 92(6), 1002–1006 (2002).
  MedlineGoogle Scholar
• 3. Anderson JO, Thundiyil JG, Stolbach A. Clearing the air: a review of the effects of particulate matter air pollution on human health. J. Med. Toxicol. Off. J. Am. Coll. Med. Toxicol. 8(2), 166–175 (2012).
  Medline CASGoogle Scholar
• 4. Stämpfli MR, Anderson GP. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat. Rev. Immunol. 9(5), 377–384 (2009).
  MedlineGoogle Scholar
• 5. Strzelak A, Ratajczak A, Adamiec A, Feleszko W. Tobacco smoke induces and alters immune responses in the lung triggering inflammation, allergy, asthma and other lung diseases: a mechanistic review. Int. J. Environ. Res. Public Health 15(5), 1033 (2018).
  MedlineGoogle Scholar
• 6. Singh D, Agusti A, Anzueto A et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur. Respir. J. 53(5), (2019).
  Google Scholar
• 7. Woodruff PG, Barr RG, Bleecker E et al. Clinical significance of symptoms in smokers with preserved pulmonary function. N. Engl. J. Med. 374(19), 1811–1821 (2016).
  Medline CASGoogle Scholar
• 8. Bazzan E, Semenzato U, Turato G et al. Symptomatic smokers without COPD have physiological changes heralding the development of COPD. ERJ Open Res. 8(2), (2022).
  MedlineGoogle Scholar
• 9. Han MK, Agusti A, Celli BR et al. From GOLD 0 to pre-COPD. Am. J. Respir. Crit. Care Med. 203(4), 414–423 (2021).
  MedlineGoogle Scholar
• 10. da Silva AL, Cruz FF, Rocco PRM, Morales MM. New perspectives in nanotherapeutics for chronic respiratory diseases. Biophys. Rev. 9(5), 793–803 (2017).
  MedlineGoogle Scholar
• 11. Huang F, Dempsey C, Chona D, Suh J. Quantitative nanoparticle tracking: applications to nanomedicine. Nanomedicine (Lond.) 6(4), 693–700 (2011).
  CASGoogle Scholar
• 12. Cheng W, Liu Y, Tang J et al. Carbon content in airway macrophages and genomic instability in Chinese carbon black packers. Arch. Toxicol. 94(3), 761–771 (2020).
  Medline CASGoogle Scholar
• 13. Bai Y, Bové H, Nawrot TS, Nemery B. Carbon load in airway macrophages as a biomarker of exposure to particulate air pollution; a longitudinal study of an international panel. Part Fibre Toxicol. 15(1), 14 (2018).
  MedlineGoogle Scholar
• 14. Comfort N, Cai K, Bloomquist TR et al. Nanoparticle tracking analysis for the quantification and size determination of extracellular vesicles. J. Vis. Exp. (169), (2021).
  MedlineGoogle Scholar
• 15. Buxton DB, Lee SC, Wickline SA, Ferrari M. Recommendations of the national heart, lung, and blood institute nanotechnology working group. Circulation 108(22), 2737–2742 (2003).
  MedlineGoogle Scholar
• 16. Ophir N, Bar Shai A, Korenstein R et al. Functional, inflammatory and interstitial impairment due to artificial stone dust ultrafine particles exposure. Occup. Environ. Med. 76(12), 875–879 (2019).
  MedlineGoogle Scholar
• 17. Fireman E, Edelheit R, Stark M, Shai AB. Differential pattern of deposition of nanoparticles in the airways of exposed workers. J. Nanoparticle Res. 19(2), 30 (2017).
  Google Scholar
• 18. Virmani T, Kumar G, Virmani R et al. Nanocarrier-based approaches to combat chronic obstructive pulmonary disease. Nanomedicine (Lond.) 17(24), 1833–1854 (2022).
  CASGoogle Scholar
• 19. Bar-Shai A, Alcalay Y, Sagiv A et al. Fingerprint of lung fluid ultrafine particles, a novel marker of acute lung inflammation. Respiration 90(1), 74–84 (2015). •• Assess the role of ultra-fine particles in lung fluid of mice as markers of inflammation.
  Medline CASGoogle Scholar
• 20. Lee S-D, Huang M-S, Kang J et al. The COPD assessment test (CAT) assists prediction of COPD exacerbations in high-risk patients. Respir. Med. 108(4), 600–608 (2014).
  MedlineGoogle Scholar
• 21. Crapo RO, Casaburi R, Coates AL et al. ATS statement: guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 166(1), 111–117 (2002).
  MedlineGoogle Scholar
• 22. Graham BL, Steenbruggen I, Miller MR et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am. J. Respir. Crit. Care Med. 200(8), e70–e88 (2019).
  MedlineGoogle Scholar
• 23. King GG, Bates J, Berger KI et al. Technical standards for respiratory oscillometry. Eur. Respir. J. 55(2), (2020).
  Google Scholar
• 24. Weiszhar Z, Horvath I. Induced sputum analysis: step by step. Breathe 9(4), 300–306 (2013).
  Google Scholar
• 25. Hacievliyagil SS, Gunen H, Mutlu LC et al. Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease. Respir. Med. 100(5), 846–854 (2006).
  MedlineGoogle Scholar
• 26. Huang A-X, Lu L-W, Liu W-J, Huang M. Plasma inflammatory cytokine IL-4, IL-8, IL-10, and TNF-α levels correlate with pulmonary function in patients with asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 22, 2800–2808 (2016).
  Medline CASGoogle Scholar
• 27. Hollander C, Sitkauskiene B, Sakalauskas R et al. Serum and bronchial lavage fluid concentrations of IL-8, SLPI, sCD14 and sICAM-1 in patients with COPD and asthma. Respir. Med. 101(9), 1947–1953 (2007).
  MedlineGoogle Scholar
• 28. Gorska K, Nejman-Gryz P, Paplinska-Goryca M et al. Comparative study of IL-33 and IL-6 levels in different respiratory samples in mild-to-moderate asthma and COPD. COPD J. Chronic Obstr. Pulm. Dis. 15(1), 36–45 (2018).
  Google Scholar
• 29. Deveci SE, Deveci F, Açik Y, Ozan AT. The measurement of exhaled carbon monoxide in healthy smokers and non-smokers. Respir. Med. 98(6), 551–556 (2004).
  MedlineGoogle Scholar
• 30. Liu H, Li J, Ma Q et al. Chronic exposure to diesel exhaust may cause small airway wall thickening without lumen narrowing: a quantitative computerized tomography study in Chinese diesel engine testers. Part Fibre Toxicol. 18(1), 14 (2021).
  Medline CASGoogle Scholar
• 31. Fireman Klein E, Adir Y, Krencel A et al. Ultrafine particles in airways: a novel marker of COPD exacerbation risk and inflammatory status. Int. J. Chron. Obstruct. Pulmon. Dis. 14, 557–564 (2019). •• Addresses ultrafine particle characteristics among chronic obstructive pulmonary disease patients.
  MedlineGoogle Scholar
• 32. Regan EA, Lynch DA, Curran-Everett D et al. Clinical and radiologic disease in smokers with normal spirometry. JAMA Intern. Med. 175(9), 1539–1549 (2015).
  MedlineGoogle Scholar
• 33. Dutta A, Roychoudhury S, Chowdhury S, Ray MR. Changes in sputum cytology, airway inflammation and oxidative stress due to chronic inhalation of biomass smoke during cooking in premenopausal rural Indian women. Int. J. Hyg. Environ. Health 216(3), 301–308 (2013). • Describes the effect of smoke inhalation on sputum characteristics.
  Medline CASGoogle Scholar
• 34. Chisholm JF, Shenoy SK, Shade JK et al. Nanoparticle diffusion in spontaneously expectorated sputum as a biophysical tool to probe disease severity in COPD. Eur. Respir. J. 54(2), (2019). • Describes the role of nanoparticle diffusion as a tool for chronic obstructive pulmonary disease severity.
  MedlineGoogle Scholar
• 35. Fireman E, Lerman Y, Stark M et al. A novel alternative to environmental monitoring to detect workers at risk for beryllium exposure-related health effects. J. Occup. Environ. Hyg. 11(12), 809–818 (2014).
  Medline CASGoogle Scholar
• 36. Hiraiwa K, van Eeden SF. Contribution of lung macrophages to the inflammatory responses induced by exposure to air pollutants. Mediators Inflamm. 2013, 619523 (2013).
  MedlineGoogle Scholar
• 37. Comandini A, Rogliani P, Nunziata A et al. Biomarkers of lung damage associated with tobacco smoke in induced sputum. Respir. Med. 103(11), 1592–1613 (2009).
  MedlineGoogle Scholar
• 38. Wei J, Xiong X-F, Lin Y-H et al. Association between serum interleukin-6 concentrations and chronic obstructive pulmonary disease: a systematic review and meta-analysis. Peer J. 3, e1199 (2015).
  MedlineGoogle Scholar
• 39. Silva BSA, Lira FS, Ramos D et al. Severity of COPD and its relationship with IL-10. Cytokine 106, 95–100 (2018).
  Medline CASGoogle Scholar
• 40. MacNee W, Donaldson K. Mechanism of lung injury caused by PM10 and ultrafine particles with special reference to COPD. Eur. Respir. J. 21(Suppl. 40), S47–S51 (2003). • Assesses the mechanism for lung injury by inhaled particles.
  Google Scholar
• 41. Guiedem E, Pefura-Yone EW, Ikomey GM et al. Cytokine profile in the sputum of subjects with post-tuberculosis airflow obstruction and in those with tobacco related chronic obstructive pulmonary disease. BMC Immunol. 21(1), 52 (2020).
  Medline CASGoogle Scholar
• 42. Fabbri LM. Smoking, not COPD, as the disease. N. Engl. J. Med. 374(19), 1885–1886 (2016).
  Medline CASGoogle Scholar
• 43. Brown JS, Zeman KL, Bennett WD. Ultrafine particle deposition and clearance in the healthy and obstructed lung. Am. J. Respir. Crit. Care Med. 166(9), 1240–1247 (2002). • Describes in detail the airway particle composition among patients with obstructive lung disease.
  MedlineGoogle Scholar
• 44. Khatri M, Bello D, Martin J et al. Chronic upper airway inflammation and systemic oxidative stress from nanoparticles in photocopier operators: mechanistic insights. NanoImpact 5, 133–145 (2017).
  Google Scholar
• 45. Khatri M, Bello D, Pal AK et al. Toxicological effects of PM 0.25–2.0 particles collected from a photocopy center in three human cell lines. Inhal. Toxicol. 25(11), 621–632 (2013).
  Medline CASGoogle Scholar